Huons Global Co. Ltd (084110) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Huons Global Co. Ltd KRW 63,900, price KRW 21,300, upside +200.0%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Huons Global Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 14,641 KRW – 74,638 KRW · fair‑value band 44,730 KRW – 83,070 KRW · the 21,300 KRW price screens below the 63,900 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Huons Global Co. in your weekly email
Every Wednesday you see whether Huons Global Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally.
Show more
Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, other chemotherapeutic, and others; and injections in the areas of anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and others, as well as circulatory, respiratory, and other tissue cell systems. It also provides medical devices, eye drop products, and bio products. The company was formerly known as Huons Co., Ltd. and changed its name to Huons Global Co., Ltd. in June 2016. Huons Global Co., Ltd. was founded in 1965 and is headquartered in Seongnam, South Korea.
Stock analysis
Huons Global Co. Ltd (084110) currently trades at 21,300 KRW, while our model-based Fair Value estimate is 63,900 KRW, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 87,692 KRW per share, and 24 of the 24 models we run sit above the 21,300 KRW price.
Bear case: the Asset-Based group reads lowest at 33,765 KRW, and 0 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 44,730 KRW (bear) to 83,070 KRW (bull), the price of 21,300 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Huons Global Co. Ltd reported revenue of 847B KRW in FY2025 versus 575B KRW in FY2021, a compound +10.2%/yr. Reported net income was 28.8B KRW in FY2025, compounding +63.9%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 296B KRW (≈ $207M) · P/S ratio 0.45 · Dividend yield 1.5% · Net margin 3.4% · Return on equity 502% · Return on assets (EBIT) 5.2% · Operating margin 11.5% · Revenue (TTM) 659B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).
What moves the price
The share trades about 71% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at 200%, 084110 screens cheaper than that median.
Fair Value models
Bear 44,730 KRWFair Value 63,900 KRWBull 83,070 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
’13
’14
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.2%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2% vs −25%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 11%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −4.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 56 stocks
Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+200% · Top 25%
Profitability
Return on assets4% · Above median
Net margin (TTM)0% · Bottom 25%
Operating margin (TTM)12% · Top 25%
Growth and dividend
Revenue growth18% · Above median
Dividend yield (TTM)1.5% · Above median
Balance sheet
Debt / equity0.18× · Highest 25%
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Huons Global Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/084110
Frequently asked questions
Is Huons Global Co. Ltd (084110) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 63,900 KRW versus a price of 21,300 KRW, about +200% upside (undervalued).
What is the fair value of 084110?
Our model-based fair value for Huons Global Co. Ltd is 63,900 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 21,300 KRW.
What is the quality score of 084110?
Huons Global Co. Ltd has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Huons Global Co. Ltd (084110)?
Our model-based price target is the fair value of 63,900 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 44,730 KRW, optimistic scenario 83,070 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Huons Global Co. Ltd stock forecast for 2026?
Our models put fair value at 63,900 KRW, about +200% upside versus a price of 21,300 KRW (undervalued). Cautious scenario 44,730 KRW, optimistic scenario 83,070 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Huons Global Co. Ltd (084110)?
Huons Global Co. Ltd reported trailing-twelve-month revenue of about 659B KRW (latest available figure, as of Sep 24, 2026).
Does Huons Global Co. Ltd pay a dividend?
Huons Global Co. Ltd currently shows a dividend yield of about 1.54% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Huons Global Co. Ltd (084110)?
For today's price to be fair in a discounted-cash-flow model, Huons Global Co. Ltd would have to grow free cash flow by -2.3 % per year for five years (discount rate 14.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 084110 use?
Our models discount Huons Global Co. Ltd at 14.1 %: a base by market capitalisation (micro), damped by beta 1.29, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Huons Global Co. Ltd that is -2.3 % per year a year over ten years, using the same discount rate (14.1 %) and the same formula as our fair value.
How much growth has Huons Global Co. Ltd (084110) delivered so far?
Over the past 5 years revenue at Huons Global Co. Ltd grew +10.1 % a year. The price currently implies -2.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Huons Global Co. Ltd (084110) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Huons Global Co. Ltd (-2.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Huons Global Co. Ltd (084110)?
The free-cash-flow yield on the price is 16.09 %: that much free cash flow Huons Global Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (14.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Huons Global Co. Ltd (084110)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Huons Global Co. Ltd it is 63,900 KRW per share (as of Sep 24, 2026), against a price of 21,300 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Huons Global Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 084110 trades below its calculated fair value: price 21,300 KRW, fair value 63,900 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 084110?
No. The price is what the market pays today (21,300 KRW); the fair value is what the company's own numbers justify (63,900 KRW). For Huons Global Co. Ltd the two are 42,600 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Huons Global Co. Ltd worth?
The market values Huons Global Co. Ltd at about 296B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 21,300 KRW; our models calculate a fair value of 63,900 KRW per share.
What do the bullish and bearish scenarios say about 084110?
Our models span a range for Huons Global Co. Ltd: cautious scenario 44,730 KRW, base 63,900 KRW, optimistic 83,070 KRW per share (as of Sep 24, 2026, price 21,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Huons Global Co. Ltd (084110)?
Balance-sheet figures for Huons Global Co. Ltd (as of Sep 24, 2026): debt of 0.18 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 084110 from its 52-week high?
Huons Global Co. Ltd trades at 21,300 KRW, about 71% below its 52-week high of 74,638 KRW and 3% above the low of 20,600 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 63,900 KRW is for.
Which stocks are comparable to Huons Global Co. Ltd?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Huons Global Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 21,300 KRW, calculated fair value 63,900 KRW (+200%), Quality Score 51/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 084110 calculated?
We run Huons Global Co. Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 63,900 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Huons Global Co. Ltd currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Huons Global Co. Ltd (084110)?
The closing price on Sep 23, 2026 was 21,300 KRW. Our model-based fair value is 63,900 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Huons Global Co. Ltd right now?
The price is below even our cautious bear case (44,730 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (44,730 KRW to 83,070 KRW) leaves room in how you read the outcome.
Key figures of Huons Global Co. Ltd
How large is the market capitalisation of Huons Global Co. Ltd (084110)?
The market capitalisation of Huons Global Co. Ltd is 296B KRW (≈ $207M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Huons Global Co. Ltd (084110)?
The price-to-sales ratio of Huons Global Co. Ltd is 0.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Huons Global Co. Ltd (084110)?
The dividend yield of Huons Global Co. Ltd is 1.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Huons Global Co. Ltd (084110)?
The net margin of Huons Global Co. Ltd is 3.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Huons Global Co. Ltd (084110)?
The return on equity (ROE) of Huons Global Co. Ltd is 502% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Huons Global Co. Ltd (084110)?
On an EBIT basis the return on assets of Huons Global Co. Ltd is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Huons Global Co. Ltd (084110)?
The operating margin of Huons Global Co. Ltd is 11.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Huons Global Co. Ltd (084110)?
Revenue at Huons Global Co. Ltd is growing +17.5% versus a year earlier (3y avg +8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Huons Global Co. Ltd (084110)?
Earnings per share at Huons Global Co. Ltd are growing +36.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Huons Global Co. Ltd (084110) carry?
The net debt of Huons Global Co. Ltd is 110B KRW (fiscal year 2025, ≈ 2.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Huons Global Co. Ltd in the live analysis
One click puts Huons Global Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
